News

New R01 to support development of novel vascular disrupting agent in combination with HIF2 antagonist for effective treatment of kidney cancer.

We are excited to have been awarded a new R01 from the National Cancer Institute "Vascular Image-Guided Optimization of Response (VIGOR)to Therapy in Kidney Cancer" to develop effective therapy using a novel vascular disrupting agent in combination with the HIF2 antagonist.  The project continues a collaboration with Professor Kevin Pinney and Dr. Mary Lynn Trawick of Baylor University who originally invented OXi8007.  It exploits non-invasive bioluminescence imaging and the latest multispectral optoacoustic tomography to evaluate new tumor models developed by the UTSW Kidney SPORE.